Rapid communication

Plasma interleukin-35 in children with Autism

Destanie Rose, Paul Ashwood

Research output: Contribution to journalArticle

Abstract

In autism spectrum disorders (ASD) many individuals have co-morbid immune dysregulation that can lead to inflammation in the brain and periphery. The novel cytokine interleukin (IL)-35 has described anti-inflammatory properties; however, the plasma levels of IL-35 in children with ASD have never been investigated. The plasma levels of IL-35 were measured by an enzyme-linked immunosorbent assay in 30 children with ASD and 39 typically developing (TD) controls. In the current study, we found that plasma IL-35 levels were significantly decreased in children with ASD compared with TD children. Furthermore, lower IL-35 levels were associated with worse behaviors as assessed using the aberrant behavior checklist. These findings are in line with other observations of decreased regulatory cytokines such as transforming growth factor beta and IL-10 in ASD, and associations with severity of behaviors. In conclusion, regulating the expression of IL-35 may provide a new possible target for the treatment of immune issues in ASD to address an imbalance between pro- and anti-inflammatory signals that alter the behavioral phenotype.

Original languageEnglish (US)
Article number152
JournalBrain Sciences
Volume9
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Interleukins
Autistic Disorder
Communication
Anti-Inflammatory Agents
Cytokines
Encephalitis
Checklist
Transforming Growth Factor beta
Interleukin-10
Autism Spectrum Disorder
Enzyme-Linked Immunosorbent Assay
Phenotype

Keywords

  • Anti-inflammatory
  • Autism spectrum disorders
  • Cytokines
  • IL-35
  • Immune regulation
  • Interleukin

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Rapid communication : Plasma interleukin-35 in children with Autism. / Rose, Destanie; Ashwood, Paul.

In: Brain Sciences, Vol. 9, No. 7, 152, 01.07.2019.

Research output: Contribution to journalArticle

@article{2ec70b973d07440f81d7565e6fc9be8e,
title = "Rapid communication: Plasma interleukin-35 in children with Autism",
abstract = "In autism spectrum disorders (ASD) many individuals have co-morbid immune dysregulation that can lead to inflammation in the brain and periphery. The novel cytokine interleukin (IL)-35 has described anti-inflammatory properties; however, the plasma levels of IL-35 in children with ASD have never been investigated. The plasma levels of IL-35 were measured by an enzyme-linked immunosorbent assay in 30 children with ASD and 39 typically developing (TD) controls. In the current study, we found that plasma IL-35 levels were significantly decreased in children with ASD compared with TD children. Furthermore, lower IL-35 levels were associated with worse behaviors as assessed using the aberrant behavior checklist. These findings are in line with other observations of decreased regulatory cytokines such as transforming growth factor beta and IL-10 in ASD, and associations with severity of behaviors. In conclusion, regulating the expression of IL-35 may provide a new possible target for the treatment of immune issues in ASD to address an imbalance between pro- and anti-inflammatory signals that alter the behavioral phenotype.",
keywords = "Anti-inflammatory, Autism spectrum disorders, Cytokines, IL-35, Immune regulation, Interleukin",
author = "Destanie Rose and Paul Ashwood",
year = "2019",
month = "7",
day = "1",
doi = "10.3390/brainsci9070152",
language = "English (US)",
volume = "9",
journal = "Brain Sciences",
issn = "2076-3425",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

TY - JOUR

T1 - Rapid communication

T2 - Plasma interleukin-35 in children with Autism

AU - Rose, Destanie

AU - Ashwood, Paul

PY - 2019/7/1

Y1 - 2019/7/1

N2 - In autism spectrum disorders (ASD) many individuals have co-morbid immune dysregulation that can lead to inflammation in the brain and periphery. The novel cytokine interleukin (IL)-35 has described anti-inflammatory properties; however, the plasma levels of IL-35 in children with ASD have never been investigated. The plasma levels of IL-35 were measured by an enzyme-linked immunosorbent assay in 30 children with ASD and 39 typically developing (TD) controls. In the current study, we found that plasma IL-35 levels were significantly decreased in children with ASD compared with TD children. Furthermore, lower IL-35 levels were associated with worse behaviors as assessed using the aberrant behavior checklist. These findings are in line with other observations of decreased regulatory cytokines such as transforming growth factor beta and IL-10 in ASD, and associations with severity of behaviors. In conclusion, regulating the expression of IL-35 may provide a new possible target for the treatment of immune issues in ASD to address an imbalance between pro- and anti-inflammatory signals that alter the behavioral phenotype.

AB - In autism spectrum disorders (ASD) many individuals have co-morbid immune dysregulation that can lead to inflammation in the brain and periphery. The novel cytokine interleukin (IL)-35 has described anti-inflammatory properties; however, the plasma levels of IL-35 in children with ASD have never been investigated. The plasma levels of IL-35 were measured by an enzyme-linked immunosorbent assay in 30 children with ASD and 39 typically developing (TD) controls. In the current study, we found that plasma IL-35 levels were significantly decreased in children with ASD compared with TD children. Furthermore, lower IL-35 levels were associated with worse behaviors as assessed using the aberrant behavior checklist. These findings are in line with other observations of decreased regulatory cytokines such as transforming growth factor beta and IL-10 in ASD, and associations with severity of behaviors. In conclusion, regulating the expression of IL-35 may provide a new possible target for the treatment of immune issues in ASD to address an imbalance between pro- and anti-inflammatory signals that alter the behavioral phenotype.

KW - Anti-inflammatory

KW - Autism spectrum disorders

KW - Cytokines

KW - IL-35

KW - Immune regulation

KW - Interleukin

UR - http://www.scopus.com/inward/record.url?scp=85068646421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068646421&partnerID=8YFLogxK

U2 - 10.3390/brainsci9070152

DO - 10.3390/brainsci9070152

M3 - Article

VL - 9

JO - Brain Sciences

JF - Brain Sciences

SN - 2076-3425

IS - 7

M1 - 152

ER -